AstraZeneca (AZN) Issues Earnings Results

AstraZeneca (NYSE:AZN) announced its quarterly earnings data on Friday. The company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.20, Morningstar.com reports. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The firm had revenue of $5.18 billion during the quarter, compared to analysts’ expectations of $5.24 billion. During the same quarter last year, the firm posted $0.99 earnings per share. The company’s revenue for the quarter was down 4.2% compared to the same quarter last year. AstraZeneca updated its FY18 guidance to $3.30-3.50 EPS.

AstraZeneca opened at $36.33 on Friday, MarketBeat.com reports. AstraZeneca has a twelve month low of $28.43 and a twelve month high of $36.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. The company has a market capitalization of $92.30 billion, a PE ratio of 8.49, a P/E/G ratio of 1.94 and a beta of 0.61.

A number of brokerages have commented on AZN. ValuEngine cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 7th. BMO Capital Markets reissued a “buy” rating and issued a $38.00 price objective on shares of AstraZeneca in a research note on Friday, January 26th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Jefferies Group raised AstraZeneca from a “hold” rating to a “buy” rating and raised their price objective for the company from $28.43 to $36.70 in a research note on Monday, March 19th. Finally, Sanford C. Bernstein raised their price objective on AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $38.12.

Several hedge funds have recently bought and sold shares of AZN. American International Group Inc. bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $1,976,000. Point72 Asset Management L.P. lifted its holdings in shares of AstraZeneca by 214.0% in the first quarter. Point72 Asset Management L.P. now owns 2,905,535 shares of the company’s stock valued at $101,607,000 after purchasing an additional 1,980,335 shares in the last quarter. Crawford Investment Counsel Inc. lifted its holdings in shares of AstraZeneca by 168.5% in the first quarter. Crawford Investment Counsel Inc. now owns 1,615,981 shares of the company’s stock valued at $56,511,000 after purchasing an additional 1,014,119 shares in the last quarter. Hardman Johnston Global Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $35,125,000. Finally, Two Sigma Investments LP bought a new position in shares of AstraZeneca in the fourth quarter valued at approximately $30,768,000. Institutional investors own 15.18% of the company’s stock.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Earnings History for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply